Dimensional Fund Advisors’s Design Therapeutics DSGN Stock Holding History
Bought
Maintained
Sold
Other funds holding DSGN
SOCM
RCM
BBA
LGM
DCM
VC
AC
VCM
Dimensional Fund Advisors's DSGN Position: Q1 2026 in Review
Dimensional Fund Advisors increased its Design Therapeutics (DSGN) stake by 45% in Q1 2026, buying an estimated $1.36M and bringing the position to 431,840 shares worth $4.59M. The position accounts for ﹤0.01% of the portfolio, ranked #2522.
Dimensional Fund Advisors first reported a position in DSGN in Q2 2022 and has held it in 16 quarters since. 125 funds tracked by Wall St. Rank hold DSGN as of Q1 2026.
- Dimensional Fund Advisors held 431,840 shares of Design Therapeutics worth $4.59M as of Q1 2026.
- Dimensional Fund Advisors bought 133,919 Design Therapeutics shares in Q1 2026, an estimated $1.36M.
- Design Therapeutics made up ﹤0.01% of Dimensional Fund Advisors's portfolio in Q1 2026, its #2522 holding.
- Dimensional Fund Advisors first reported a position in Design Therapeutics in Q2 2022 and has held it in 16 quarters since.
- 125 funds tracked by Wall St. Rank held Design Therapeutics as of Q1 2026.
Based on Dimensional Fund Advisors's 13F filing for Q1 2026, filed 7 May 2026.